浙農股份(002758.SZ):2.12億元受讓穎泰生物3.26%的股份
格隆匯10月7日丨浙農股份(002758.SZ)公佈,公司下屬浙農合泰(杭州)企業管理合夥企業(有限合夥)通過大宗交易方式受讓持有北京穎泰嘉和生物科技股份有限公司3.26%股份,交易價格為5.3元/股,交易總額為2.12億元。
後續,公司和下屬企業將與穎泰生物在農化等領域,就產品、市場、渠道及產業鏈的拓展等方面開展全面、深入的戰略合作,實現優勢互補、互利共贏。
浙農合泰投資穎泰生物,將有利於公司通過資本紐帶加強與穎泰生物的業務合作,依託其研發、生產優勢,以及公司在國內市場、渠道方面優勢,在飛防專用製劑、原藥、復配製劑等研發、生產、銷售上開展合作,深化產品供應鏈合作,推進銷售渠道共享,促成雙方合作共贏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.